Bristol-Myers Squibb
BMY Big PharmaOncology and immunology leader with Opdivo, Revlimid, and Eliquis franchises. Known for strategic acquisitions including Celgene and recent cell therapy deals.
FDA Novel Drug Designations
(2017-2024)See 10 novel approvals →
Bristol-Myers Squibb at a Glance
- Leading 13 drug targets across portfolio
- Fast trial execution (20 months median completion)
Bristol-Myers Squibb's Key Drugs
Bristol-Myers Squibb's core commercial portfolio centers on OPDIVO, ELIQUIS, YERVOY, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.
Melanoma
Stroke Prevention
Unresectable or metastatic melanoma
Anemia
Bristol-Myers Squibb News
All Bristol-Myers Squibb news →- Nov 12, 2026 CorporateBristol Myers Squibb Announces Evolution of Research & Development Organization ↗
- Nov 6, 2026 TrialsBristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions ↗
- Oct 29, 2026 EarningsBristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook ↗
- Oct 23, 2026 TrialsIzalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study ↗
- Oct 23, 2026 TrialsBristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 ↗
Bristol-Myers Squibb's Recent FDA Approvals
Bristol-Myers Squibb secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Bristol-Myers Squibb's Therapeutic Areas
Bristol-Myers Squibb's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 9 biologic and 24 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Bristol-Myers Squibb's Top Competitors
Bristol-Myers Squibb's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Bristol-Myers Squibb Pipeline Snapshot
Bristol-Myers Squibb has 877 active clinical programs from ClinicalTrials.gov — 220 Phase 3, 243 Phase 2 and 414 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 113/184 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (23)
Discontinued (1)
Company Info
- First Approval
- 1945-02-20
- Latest
- 2026-10-20
- Applications
- 135
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges